PD 166285 CAS: 212391-63-4
MF: C26H27Cl2N5O2•2HCl
MW: 585.35
An inhibitor of RTK, c-Src, FGFR1, Wee 1, and PDGFRβ.

PD 166285 (CAS 212391-63-4)

PD 166285 | CAS 212391-63-4 is rated 5.0 out of 5 by 1.
  • y_2021, m_7, d_31, h_19
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.18
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_208153, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 7ms
  • REVIEWS, PRODUCT
loading
5
1
4
0
3
0
2
0
1
0
Alternate Names: Heparin-Cantithrombin II
Application: PD 166285 is an inhibitor of RTK, c-Src, FGFR1, Wee 1, and PDGFRβ
CAS Number: 212391-63-4
Purity: ≥98%
Molecular Weight: 585.35
Molecular Formula: C26H27Cl2N5O22HCl
Supplemental Information: This is classified as a Dangerous Good for transport and may be subject to additional shipping charges.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data (including water content).
loading

PD 166285 is a potent inhibitor of the tyrosine kinases c-Src, Flg (fibroblast growth factor receptor 1, FGFR1), and PDGFRβ (platelet-derived growth factor receptor β) (IC50 values are 8.4, 39.3 and 98.3 nM respectively). PD 166285 also inhibits the checkpoint kinases Wee1 and MYT1 (Myt1), abolishes Cdc2 phosphorylation in numerous tumor cell lines, and abrogates the G2 checkpoint. PD 166285 is an RTK inhibitor with broad-spectrum properties and displays anti-angiogenic activity and anti-tumor efficacy when used with PDT (photodynamic therapy). PD 166285 is an inhibitor of EGFR.


References

Star, W., et al.: Cancer Res., 46, 2532 (1986), Sawutz, D., et al.: Biochem. Pharm., 51, 1631 (1996), Voest, E., et al.: Anti-Cancer Drugs, 7, 723 (1996), Connolly, C., et al.: Bioorg. Med. Chem. Lett., 7(18), 2415 (1997), Hamby, J., et al.: J. Med. Chem., 40, 2296 (1997)

Physical State :
Solid
Solubility :
Soluble in water, methanol, and DMSO (100 mM).
Storage :
Store at 4° C
Melting Point :
236-241° C
Refractive Index :
n20D ~1.64 (Predicted)
IC50 :
c-Src: IC50 = 8.4 nM; Wee 1: IC50 = 24 nM; Flg: IC50 = 39.3 nM; MYT1: IC50 = 72 nM; EGFR: IC50 = 87.5 nM
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
PubChem CID :
MDL Number :
MFCD18086890
SMILES :
CCN(CC)CCOC1=CC=C(C=C1)NC2=NC=C3C=C(C(=O)N(C3=N2)C)C4=C(C=CC=C4Cl)Cl.Cl.Cl

Download SDS (MSDS)

Certificate of Analysis

Adobe Acrobat Reader is required to reliably view,
print and comment on PDF documents

PD 166285 (CAS 212391-63-4)  Product Citations

See how others have used PD 166285 (CAS 212391-63-4). Click on the entry to view the PubMed entry .

Citations 1 to 2 of 2 total

PMID: # 29941193  Platzer, C.|Najjar, A.|Rohe, A.|Erdmann, F.|Sippl, W.|Schmidt, M.| et al. 2018. Bioorg Med Chem. 26: 4014-4024.

PMID: # 24229357  Rohe, A. et al. 2014. Assay Drug Dev Technol. 12: 136-44.

Citations 1 to 2 of 2 total
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 6ms
  • QUESTIONS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
Rated 5 out of 5 by from Leijen Leijen, S. et al. (PubMed 20406171) reported that abrogation of the G2 checkpoint by inhibition of Wee-1 kinase by PD 166285 results in sensitization of p53-deficient tumor cells to DNA-damaging agents. -SCBT Publication Review
Date published: 2015-04-11
  • y_2021, m_7, d_31, h_19
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.18
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_208153, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 6ms
  • REVIEWS, PRODUCT